CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance. Lipert BA, Siemens KN, Khan A, Airey R, et al. Breast Cancer Res 2025;27:48.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lipert BA, Siemens KN, Khan A, Airey R, et al. CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance. Breast Cancer Res 2025;27:48.
PMID: 40165206